Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MBG453 in Lower Risk MDS
NCT04823624 · Massachusetts General Hospital · PHASE2 · terminated · last registry update 2026-10-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial closed early due to changes in support for the study drug.” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HAVCR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-20Results posted on the registry: Diwakar Davar, Dostarlimab (TSR-042) (singly) + Dostarlimab (TSR-042) and TSR-022 (combination) (NCT04139902)
- 2026-07-01Results posted on the registry: GlaxoSmithKline, Cobolimab + Dostarlimab (NCT04655976)
- 2026-03-27Results posted on the registry: Hoffmann-La Roche, Lomvastomig + Tobemstomig (NCT04785820)
- 2026-01-13Also stopped (terminated): Novartis Pharmaceuticals, MBG453 + Placebo (NCT03946670)
- 2026-01-13Also stopped (terminated): Novartis Pharmaceuticals, MBG453 + Venetoclax (NCT04150029)
- 2026-01-13Also stopped (terminated): Novartis Pharmaceuticals, Sabatolimab + Azacitidine (NCT04266301)
- 2025-12-12Results posted on the registry: Novartis Pharmaceuticals, Sabatolimab + Azacitidine (NCT04266301)
- 2025-11-17Results posted on the registry: Novartis Pharmaceuticals, MBG453 + Venetoclax (NCT04150029)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision